Featured Research

from universities, journals, and other organizations

A Second Type Of Botulinum Toxin -- Btx-B -- May Be Effective For Treating Face Wrinkles

Date:
June 24, 2002
Source:
University Of California - San Francisco
Summary:
A second type of Botulinum toxin - type B (brand name Myobloc®) -- may be as effective as type A (brand name Botox®) for the treatment of facial wrinkles, according to UCSF researchers. The study, among the first to analyze the effectiveness of type B in prospective clinical trial, appears in the current issue of Otolaryngology - Head and Neck Surgery.

A second type of Botulinum toxin - type B (brand name Myobloc®) -- may be as effective as type A (brand name Botox®) for the treatment of facial wrinkles, according to UCSF researchers. The study, among the first to analyze the effectiveness of type B in prospective clinical trial, appears in the current issue of Otolaryngology - Head and Neck Surgery.

Unlike type A, type B is stable at room temperature, increasing its ease of use and shelf life, according to Corey S. Maas, MD, chief of the UCSF division of facial plastic surgery and lead author of the study. He explained that Type A is supplied as a powder that must be stored frozen, and once reconstituted, refrigerated and used within a few days. The researchers noted that type B may also be appropriate for patients who do not respond to type A because they have resistant or altered target sites for the drug or have developed antibodies to type A because of frequent treatments.

According to the researchers, patients injected with type B had a more rapid onset of wrinkle reduction (within 48 hours as compared to 3-7 days for type A), but the effect did not last as long (6-8 weeks as opposed to 12-14 weeks for type A), due to the low dose studied.

Though the duration of effectiveness of the drug at higher doses is yet to be determined, type B may be particularly cost-effective for patients who need only small amounts or "touch-ups," said Maas. "Physicians using type B will be able to go to the refrigerator and draw up even a small amount, without worrying about the costs of reconstituting a new vial," he said.

Botulinum toxin B was licensed by the Federal Drug Administration (FDA) in January 2001 for treatment of cervical dystonia -- a spastic contraction of neck muscles. Like botulinum toxin A, toxin B is an artificially produced neuromuscular paralyzing agent. When either toxin is injected into the muscle, it binds to nerve endings. Once in the nerve terminal, the toxin cuts proteins so that the nerve terminal is no longer able to release a neurotransmitter called acetylcholine. Without acetylcholine, nerve impulses can no longer make muscles contract. Without muscle contraction -- in the forehead and near the eyes and mouth -- wrinkles can no longer occur in these areas, said Maas.

Types A and B are two distinct medicines and are not necessarily interchangeable for all uses, said Maas. Though more studies are needed, type B may be as effective as type A for treating face wrinkles and perhaps better adapted than type A for treating conditions of excessive sweating known as hyperhydrosis. This is because type B seems to have an affinity for the sweat and salivary gland nerve terminals that may produce dryness side effects, he explained.

In addition to use in prevention of wrinkles and treating excessive sweating, botulinum type A has been used to treat uncontrolled eye twitching, crossed eyes, muscle spasms and migraine headaches. Future studies will determine if type B can be safe and effective in treating these conditions.

The researchers noted that doses of botulinum type B (800 units) injected into the muscles of the brow, eyes and forehead were well tolerated and led to no major side effects through twelve weeks of physician follow-up. Investigators followed 67 patients were who evaluated at 1, 2, 4, 8 and 12 weeks after treatment. Further studies of botulinum type B are necessary to determine the appropriate doses for the best clinical outcomes, said Maas.

Additional researchers on this study include: Jay B. Reeck, MD, and Alexander L. Ramirez, MD, both residents in the UCSF department of otolaryngology.

Funding for this study was provided by Elan Pharmaceuticals, which manufactures Myobloc®. Maas serves as a consultant for Elan Pharmaceuticals and is a member of the scientific advisory board for the manufacturers of Botox® and Myobloc®.


Story Source:

The above story is based on materials provided by University Of California - San Francisco. Note: Materials may be edited for content and length.


Cite This Page:

University Of California - San Francisco. "A Second Type Of Botulinum Toxin -- Btx-B -- May Be Effective For Treating Face Wrinkles." ScienceDaily. ScienceDaily, 24 June 2002. <www.sciencedaily.com/releases/2002/06/020624072107.htm>.
University Of California - San Francisco. (2002, June 24). A Second Type Of Botulinum Toxin -- Btx-B -- May Be Effective For Treating Face Wrinkles. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2002/06/020624072107.htm
University Of California - San Francisco. "A Second Type Of Botulinum Toxin -- Btx-B -- May Be Effective For Treating Face Wrinkles." ScienceDaily. www.sciencedaily.com/releases/2002/06/020624072107.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) — The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) — Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) — America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) — China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins